XLON
TRX
Market cap6mUSD
Oct 22, Last price
7.25GBP
Name
Tissue Regenix Group PLC
Chart & Performance
P/E
—
P/S
0.24
EPS
—
Div Yield, %
—
Shrs. gr., 5y
43.21%
Rev. gr., 5y
17.06%
Revenues
29m
-2.87%
Net income
-713k
L-58.38%
CFO
-2m
L
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tissue Regenix Group plc, established in 2006 and headquartered in Garforth, United Kingdom, is a medical technology enterprise dedicated to advancing the fields of tissue engineering and regenerative medicine. Operating across the United States and international markets, the company develops and commercializes sophisticated platform technologies. Its operations are organized into BioSurgery, Orthopaedics & Dental, and GBM-V & Cardiac divisions. Tissue Regenix's flagship dCELL technology involves a soft tissue decellularization process, which meticulously removes DNA and cellular material from animal and human tissues to facilitate the repair of diseased or injured body parts. Complementing this is BioRinse technology, a natural bone filler designed to stimulate and promote native bone growth through its osteoinductive properties. The company's diverse product portfolio includes DermaPure, a decellularized dermal allograft used for strengthening, repairing, and replacing compromised skin tissue, and SurgiPure XD, a decellularized porcine dermal matrix for mending hernias and body wall defects. For orthopedic applications, Tissue Regenix offers OrthoPure XT, a regenerative scaffold that allows damaged tissue to repopulate with the patient's own cells, alongside various osteoinductive bone matrices such as ConCelltrate 100 and MatrixCellect 100 DBM. Other notable products include Matrix IQ Dermis, a human-derived dermal graft engineered for revascularization and tissue repair, and Matrix OI FlexIt, a flexible demineralized cortical allograft bone sheet. The company also offers DentalFix, a mineralized particulate allograft designed to leverage the osteoconductive properties of natural bone. Its extensive product line further encompasses CardioPure solutions, Matrix OI 100 DBM for non-structural bone-grafting, Matrix OI Strips and Blocks as stem cell containment scaffolds, AmnioWorks for applications in ophthalmology and wound covering, and a variety of specialized sports medicine products.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||